Immuron Ltd ADR IMRN
News
Trading Information
- Previous Close Price
- $1.26
- Day Range
- $1.19–1.31
- 52-Week Range
- $0.68–2.39
- Bid/Ask
- $1.16 / $1.25
- Shares Outstanding
- 8.07M
- Market Cap
- $9.93M
- Volume/Avg
- 1 / 246,272
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.75
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers’ diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 7
- Website
- https://www.immuron.com.au
Valuation
|
Metric
|
IMRN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.24 |
Price/Sales | 1.75 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
IMRN
|
|---|---|
Quick Ratio | 6.75 |
Current Ratio | 8.04 |
Interest Coverage | −484.28 |
Quick Ratio
IMRN
Profitability
|
Metric
|
IMRN
|
|---|---|
Return on Assets (Normalized) | −37.23% |
Return on Equity (Normalized) | −44.27% |
Return on Invested Capital (Normalized) | −45.43% |
Return on Assets
IMRN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|R#Yh%^ | LOCK|b>#GP | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|<!tvGr& | LOCK|%WH&R | $70B | |||
| argenx SE ADR
ARGX
| LOCK|G&@<n%Q | LOCK|nV> | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|wsW$w< | LOCK|<<wv | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<yH&b# | LOCK|bxQ | $36B | |||
| Moderna Inc
MRNA
| LOCK|<$l$zrn | LOCK|T! | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|l!d<TyCW | LOCK|#$L&> | $25B | |||
| Incyte Corp
INCY
| LOCK|d!vft@^ | LOCK|>? | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|pw!%fl | LOCK|r$% | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|^@DB$Q | LOCK|!yK | $17B |
United States